In classical Hodgkin's lymphoma, 97% of patients exhibit PD‐L1 AMP.14 Compared with other cancers, patients with Hodgkin's lymphoma exhibit a higher overall response rate, reaching 69%.15, 16 In rare metastatic basal cell carcinoma, PD‐L1 AMP is also related to response to nivolumab.17 Thus, there is a strong correlation between PD‐L1 AMP and response to the PD‐1/PD‐L1 blockade. This evidence concerns the gene CD274 and basal cell carcinoma.